Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein
Alessandro Dinoto1,2, Laura Cacciaguerra1, Nisa Vorasoot1,3,4
1Department of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN.
Background And Objectives:
Data regarding late adult-onset myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are scant. This study sought to assess the frequency, characteristics, and outcome of late adult-onset MOGAD and identify differences from early adult-onset MOGAD.
Methods:
This retrospective, observational study included Mayo Clinic patients with MOGAD per 2023 diagnostic criteria and with onset age 50 years or older. Clinical, laboratory, radiologic, treatment, and outcome data were collected and compared between patients aged 50-59 years and those aged 60 years or older. Finally, the characteristics and outcome of patients with late adult-onset MOGAD (aged 50 or older) were compared with a reference group of patients with early adult-onset (aged 18-49) MOGAD (n = 141).
Results:
There were 107 patients with late adult-onset MOGAD included, representing 25% of the MOGAD cohort (n = 436). The median age at onset was 59 years (range: 50-88), and 71 (66%) were female. Medical comorbidities were noted in 86 of 105 (83%). Optic neuritis was the most frequent onset attack (77/107, 72%), and the median Expanded Disability Status Scale (EDSS) score at nadir was 3 (range: 1-9). In 32 of 107 (30%), a potential trigger was noted, mostly infections. In 32 patients (30%), an alternative diagnosis was considered before MOGAD identification, most commonly giant cell arteritis (n = 15 [11 undergoing temporal artery biopsy]). By a median follow-up duration of 22 months (range: 0-306), 50 patients (47%) had a relapsing course, and preventive treatment was administered in 53 (50%). Medication side effects were common (41/107, 38%). No differences were observed in patients with MOGAD aged 50-59 years vs 60 years or older. Lastly, late adult-onset patients had more optic nerve involvement (p = 0.015; OR: 1.9; 95% CI 1.1-3.3), brainstem/cerebellar involvement (p = 0.008; OR: 3.4; 95% CI 1.1-3.3), and cognitive decline (p = 0.01; OR: 5.3; 95% CI 1.4-19.4) and less frequent myelitis (p < 0.001; OR: 0.4; 95% CI 0.2-0.7) vs those with early adult-onset MOGAD, but EDSS scores and frequency of a relapsing course were similar.
Discussion:
Late adult-onset MOGAD accounts for one-quarter of patients with MOGAD. Optic neuritis is the dominant phenotype in this age group with MOGAD and is under-recognized and frequently misdiagnosed. Outcomes in late adult-onset MOGAD are similar to those in early adult-onset disease.
Insights
Late adult-onset myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) affects 25% of patients, often presenting with optic neuritis and comorbidities. Outcomes are similar to early adult-onset MOGAD, despite differences in neurological involvement.
Area of Science:
- Neurology
- Immunology
- Neuroimmunology
Background:
- Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) data in older adults is limited.
- Late adult-onset MOGAD (age ≥50) represents a significant portion (25%) of the MOGAD cohort.
- Medical comorbidities are prevalent in this demographic.
Purpose of the Study:
- To determine the frequency, characteristics, and outcomes of MOGAD in patients aged 50 years and older.
- To compare late adult-onset MOGAD with early adult-onset MOGAD.
- To identify differences between MOGAD patients aged 50-59 and those aged 60+.
Main Methods:
- Retrospective observational study of 107 Mayo Clinic patients with MOGAD (onset ≥50 years) using 2023 diagnostic criteria.
- Collected clinical, laboratory, radiologic, treatment, and outcome data.
- Compared late adult-onset MOGAD with a reference group of 141 early adult-onset MOGAD patients.
Main Results:
- Optic neuritis was the most frequent presentation (72%), with a median Expanded Disability Status Scale (EDSS) score of 3.
- 30% of patients had a potential trigger (infections), and 30% were initially misdiagnosed (e.g., giant cell arteritis).
- Late adult-onset MOGAD patients showed increased optic nerve, brainstem/cerebellar involvement, and cognitive decline, but similar relapse rates and EDSS scores compared to early adult-onset MOGAD.
Conclusions:
- Late adult-onset MOGAD constitutes 25% of MOGAD cases, predominantly presenting with optic neuritis.
- This condition is often under-recognized and misdiagnosed.
- Disease outcomes in late adult-onset MOGAD are comparable to those in early adult-onset MOGAD.
More Related Videos
05:44Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
Published on: October 13, 2023
08:03Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
Published on: April 15, 2014
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:15Parkinson's Disease: Overview
01:30Oppositional Defiant Disorder
Diagnostic Criteria and...